Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
5
×
biotech
clinical trials
eli lilly
fda
indiana blog main
indiana top stories
life sciences
national blog main
boston blog main
raleigh-durham blog main
raleigh-durham top stories
teva pharmaceutical
boston top stories
boulder/denver blog main
boulder/denver top stories
calcitonin gene-related peptide
chronic migraine
detroit blog main
detroit top stories
migraine research foundation
national
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
allergan
drugs
episodic migraine
eptinezumab
erenumab
What
fda
won
approval
drug
migraine
new
class
decades
developed
drugs
eli
lilly
medicines
pain
starts
acute
addresses
amgen
announced
approved
arguments
august
big
bio
biotech
busy
candidates
causes
commercialized
companies
competitors
condition
days
decision
decisions
devices
friday
gets
giant
giving
Language
unset
Current search:
won���t
×
amgen
×
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines